A prospective study of direct‐acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort
Loreta A. Kondili(Istituto Superiore di Sanità), Anna Linda Zignego(University of Florence), Massimo Puoti(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Marco Massari(Azienda Sanitaria Unità Locale di Reggio Emilia), A. Benedetti(Marche Polytechnic University), Anna Ludovica Fracanzani(University of Milan), Luchino Chessa(University of Cagliari), Mario Masarone(University of Salerno), Francesco Paolo Russo(University of Padua), Diletta Laccabue(University of Parma), Pierluigi Blanc, Monica Monti(University of Florence), Valentina Panetta, Salvatore Madonia(Ospedale Vincenzo Cervello), Andrea Iannone(University of Bari Aldo Moro), Marcello Persico(University of Salerno), Gabriella Verucchi(University of Bologna), Cesare Mazzaro(Azienda Ospedaliera Santa Maria Degli Angeli), Roberto Filomia(University of Messina), Liliana Chemello(University of Padua), Alessia Ciancio(Department of Medical Sciences), Ivan Gentile(University of Naples Federico II), Pietro Andreoné, B. Coco(Azienda Ospedaliera Universitaria Pisana), Laura Gragnani(University of Florence), Elisa Biliotti(Sapienza University of Rome), Donatella Ieluzzi(University of Verona), Maria Grazia Rumi(University of Milan), Francesco Barbaro(University of Padua), Giuseppina Brancaccio, Maria Giovanna Quaranta(Istituto Superiore di Sanità), Carmine Coppola, Filomena Morisco
Cited by 36
Related Papers
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
|The Lancet Rheumatology|2020|998
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.
|Journal of Clinical Investigation|1996|661